Association between tumor tissue TIMP-1 levels and objective response to first-line chemotherapy in metastatic breast cancer.

Abstract

In a previous study from our laboratory, high tumor levels of tissue inhibitor of metalloproteinases-1 (TIMP-1) have been associated with an adverse response to chemotherapy in metastatic breast cancer suggesting that TIMP-1, which is known to inhibit apoptosis, may be a new predictive marker in this disease. The purpose of this study was to investigate the association between TIMP-1 and objective response to chemotherapy in an independent patient population consisting of patients with metastatic breast cancer from Sweden and Denmark. TIMP-1 was measured using ELISA in 162 primary tumor extracts from patients who later developed metastatic breast cancer and these levels were related to the objective response to first-line chemotherapy. Increasing levels of TIMP-1 were associated with a decreasing probability of response to treatment, reaching borderline significance (OR = 1.59, 95% CI: 0.97-2.62, P = 0.07). This OR is very similar to the result from our previous study. Increasing levels of TIMP-1 were also associated with a shorter disease-free survival and overall survival, however, not statistically significant. The results from the present study support previous data that TIMP-1 is associated with objective response to chemotherapy for metastatic breast cancer.

• Authors: Marie Klintman, Sidse Ørnbjerg Würtz, Ib Jarle Christensen, Pernille Braemer Hertel, Mårten Fernö, Martin Malmberg, Henning Mouridsen, Frederik Cold, Anne-Sofie Schrohl, John A Foekens, Per Malmström, Nils Brünner
• Journal: Breast cancer research and treatment (Breast Cancer Res Treat) Vol. 121 Issue 2 Pg. 365-71 (Jun 2010) ISSN: 1573-7217 [Electronic] Netherlands
• PMID: 19653096 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Antineoplastic Agents
• Biomarkers, Tumor
• Tissue Inhibitor of Metalloproteinase-1

Topics

• Adult
• Antineoplastic Agents (therapeutic use)
• Biomarkers, Tumor (analysis)
• Breast Neoplasms (genetics, metabolism, mortality)
• Disease-Free Survival
• Enzyme-Linked Immunosorbent Assay
• Female
• Humans
• Middle Aged
• Prognosis
• Tissue Inhibitor of Metalloproteinase-1 (analysis, metabolism)
• Treatment Outcome